Uso da Bioinformática para selecionar moléculas candidatas a fármacos
Loading...
Date
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Universidade Federal de Juiz de Fora - Campus Avançado de Governador Valadares
DOI
Abstract
The development of new drugs can present several problems, an important
bottleneck in this process being the ability to reconcile a molecule that is a potent
pharmacological inhibitor and that also has its synthesis possible to be carried out.
Previous computational studies must be carried out to target molecules with good
pharmacokinetic parameters, high biological activity and also a great possibility of
being synthesized. Among several computational tools used in the study of new
drugs, there are those used to predict pharmacokinetic parameters. Such tools are
computational platforms of easy access and execution. After identifying and
validating a pharmacological target, for example kinase enzymes in cancer,
promising molecules can be designed for this target. If the type of cancer is brain,
studies of promising molecules with the ability to cross the blood-brain barrier can
contribute significantly. Thus, the objective of this study is to carry out computational
studies for the selection of promising molecules for the treatment of brain cancer. To
carry out this study, 98 molecules were selected. As a criterion for this selection was,
firstly, to evaluate the possibility of synthesizing these molecules. Then
computational studies were carried out to evaluate pharmacokinetic parameters,
ability to inhibit kinases and to cross the blood-brain barrier. The result obtained in
this study allowed the selection of five most promising molecules. Such molecules
can be synthesized and tested in in vitro experiments. It can be concluded, therefore,
that this study allowed the reduction of a considered high number of proposed
molecules to a reduced number of those considered more promising, thus reducing
the time and money for the development of promising molecules for the treatment of
this type of cancer.
Description
Citation
Collections
Endorsement
Review
Supplemented By
Referenced By
Creative Commons license
Except where otherwise noted, this item's license is described as Acesso Aberto

